NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
Post Views: 214 NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided a corporate update highlighting key priorities and anticipated development milestones for 2022. “We believe 2021 provided strong validation of the broad potential therapeutic benefit of…